On October 8, AstraZeneca announced that Dazhuoyou®, which was jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, was officially approved by China's National Drug Administration on September 29, 2026 to treat adult patients with unresectable or metastatic triple-negative breast cancer who are not suitable for treatment with PD-1/PD-L1 inhibitors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.